{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:04:45Z","timestamp":1779955485985,"version":"3.53.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000082","name":"Cystic Fibrosis Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000082","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jcf.2025.08.018","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T12:53:17Z","timestamp":1756731197000},"page":"923-928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Biomarkers associated with clinical response to cystic fibrosis pulmonary exacerbation treatment and adjuvant prednisone therapy"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1785-3870","authenticated-orcid":false,"given":"Bradley S.","family":"Quon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasleen K.","family":"Matta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0966-6779","authenticated-orcid":false,"given":"Michelle","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-9642","authenticated-orcid":false,"given":"Hartmut","family":"Grasemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4057-6592","authenticated-orcid":false,"given":"Felix","family":"Ratjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jcf.2025.08.018_bib0001","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic Fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jcf.2025.08.018_bib0002","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jcf.2015.03.003","article-title":"Inflammation in cystic fibrosis lung disease: pathogenesis and therapy","volume":"14","author":"Cantin","year":"2015","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.08.018_bib0003","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jcf.2024.04.004","article-title":"Update on the diagnosis and management of cystic fibrosis pulmonary exacerbations","volume":"23","author":"Cogen","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"11","key":"10.1016\/j.jcf.2025.08.018_bib0004","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1164\/rccm.202102-0461OC","article-title":"A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment","volume":"204","author":"Goss","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcf.2025.08.018_bib0005","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jcf.2022.05.010","article-title":"The effect of antibiotic changes during treatment of cystic fibrosis pulmonary exacerbations","volume":"21","author":"Zikic","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2025.08.018_bib0006","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02278-2023","article-title":"A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment","volume":"63","author":"Waters","year":"2024","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jcf.2025.08.018_bib0007","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jcf.2021.10.009","article-title":"Inflammation biomarkers in sputum for clinical trials in cystic fibrosis: current understanding and gaps in knowledge","volume":"21","author":"Lepissier","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.08.018_bib0008","unstructured":"Goss C., Caldwell E., Gries K., Leidy N., Edwards T., Flume P., et al., editors. Validation of a novel patient-reported respiratory symptoms instrument in cystic fibrosis: CFRSD-CRISS. Pediatric pulmonology; 2013: WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA."},{"issue":"5","key":"10.1016\/j.jcf.2025.08.018_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096681","article-title":"IFN-gamma stimulates autophagy-mediated clearance of Burkholderia cenocepacia in human cystic fibrosis macrophages","volume":"9","author":"Assani","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jcf.2025.08.018_bib0010","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.4110\/in.2018.18.e33","article-title":"Direct antiviral mechanisms of interferon-gamma","volume":"18","author":"Kang","year":"2018","journal-title":"Immune Netw"},{"issue":"8","key":"10.1016\/j.jcf.2025.08.018_bib0011","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.jcf.2025.08.018_bib0012","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00256-2024","article-title":"Clinical implications of innate immune exhaustion in cystic fibrosis","volume":"10","author":"Moller","year":"2024","journal-title":"ERJ Open Res"},{"issue":"3","key":"10.1016\/j.jcf.2025.08.018_bib0013","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1046\/j.1365-2249.2000.01232.x","article-title":"Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes","volume":"120","author":"Moss","year":"2000","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.jcf.2025.08.018_bib0014","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1164\/rccm.201206-1150OC","article-title":"A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection","volume":"187","author":"Tiringer","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcf.2025.08.018_bib0015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1034\/j.1600-0463.2000.d01-64.x","article-title":"The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type","volume":"108","author":"Moser","year":"2000","journal-title":"APMIS"},{"issue":"5","key":"10.1016\/j.jcf.2025.08.018_bib0016","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1378\/chest.13-0693","article-title":"Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations","volume":"144","author":"Shoki","year":"2013","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.jcf.2025.08.018_bib0017","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/thoraxjnl-2012-202538","article-title":"Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation","volume":"68","author":"Horsley","year":"2013","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.jcf.2025.08.018_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171229","article-title":"Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations","volume":"12","author":"Sharma","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jcf.2025.08.018_bib0019","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1513\/AnnalsATS.201410-493OC","article-title":"Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation","volume":"12","author":"Sagel","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"7","key":"10.1016\/j.jcf.2025.08.018_bib0020","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1164\/ajrccm.163.7.9812044","article-title":"Eotaxin expression after segmental allergen challenge in subjects with atopic asthma","volume":"163","author":"Lilly","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.jcf.2025.08.018_bib0021","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/thorax.57.8.742","article-title":"CF asthma\": what is it and what do we do about it?","volume":"57","author":"Balfour-Lynn","year":"2002","journal-title":"Thorax."},{"issue":"5","key":"10.1016\/j.jcf.2025.08.018_bib0022","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jcf.2023.02.006","article-title":"Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations","volume":"22","author":"Heltshe","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.08.018_bib0023","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcf.2017.06.002","article-title":"Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor","volume":"17","author":"Flume","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2025.08.018_bib0024","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jcf.2023.06.012","article-title":"Impact of lumacaftor\/ivacaftor and tezacaftor\/ivacaftor on treatment response in pulmonary exacerbations of F508del\/F508del cystic fibrosis","volume":"22","author":"McElvaney","year":"2023","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:36:03Z","timestamp":1779953763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325015772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1569199325015772"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.08.018","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers associated with clinical response to cystic fibrosis pulmonary exacerbation treatment and adjuvant prednisone therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}